Authors

Latest:

Dr. Eric Haura on New Biomarker Assay System for Lung Cancer

Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

Eric J. Jacobs, PhD

Latest:

Association Between BMI and Pancreatic Cancer Mortality

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.

Eric J. Sherman, MD

Latest:

Dr. Sherman on Selumetinib-Enhanced Radioiodine Uptake

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a pilot study of selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Eric J. Sherman, MD, Memorial Sloan Kettering Cancer Center

Eric J. Sherman, MD, MSKCC

Eric Jonasch, MD

Latest:

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Eric Jonasch, MD, MD Ande

Eric Jonasch, MD, MD Anders

Eric Jonasch, MD, University of Texas MD Anderson Cancer Center

Latest:

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Eric Klein, MD

Latest:

Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Eric Larsen, MD

Latest:

Dr. Larsen Discusses Outcomes for AYA ALL Patients

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Eric Liu, MD, FACS

Latest:

Dr. Liu on Medical Advancements for Neuroendocrine Tumors

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

Eric Liu, MD, FACS, Rocky Mountain Cancer Centers

Eric M. Horwitz, MD

Latest:

Dr. Horwitz on the Evolution of Radiation Therapy in Prostate Cancer

Eric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.

Eric M. Ostertag, MD, PhD

Latest:

Dr. Ostertag on Emerging CAR T Product for Myeloma

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

Eric Padron, MD

Latest:

Dr. Padron on the SRSF2 Mutation in MDS and CMML

Eric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.

Eric Pujade-Lauraine, MD, PhD

Latest:

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

Dr. Eric Pujade-Lauraine, from UniversitÃ© de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Eric Roeland, MD, UC San Diego Health

Eric Roeland, MD, University of California, San Diego

Eric S. Nadler, MD

Latest:

Dr Nadler on the Inherent Complexity of Diagnosing Sarcomas

Eric Nadler, MD, MPP, discusses the inherent complexity of diagnosing sarcomas.